https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 A retrospective analysis of nadir-neutropenia directed pegylated granulocyte-colony stimulating factor on febrile neutropenia rates in (neo)adjuvant breast cancer chemotherapy regimens. https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41071 20% in TC and TCH inroutine clinical practice should guide primary GCSF use in accordance with international guidelines.]]> Wed 10 Jan 2024 11:15:37 AEDT ]]> A retrospective analysis of nadir-neutropenia directed pegylated granulocyte-colony stimulating factor on febrile neutropenia rates in (neo)adjuvant breast cancer chemotherapy regimens https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51107 20% in TC and TCH in routine clinical practice should guide primary GCSF use in accordance with international guidelines.]]> Wed 04 Oct 2023 11:54:27 AEDT ]]> Cost-effectiveness analysis of lipegfilgrastim as primary prophylaxis in women with breast cancer in Australia: a modelled economic evaluation https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43134 Tue 13 Sep 2022 15:14:31 AEST ]]>